Market Place
Sourcing Support
Merck’s Welireg receives European approval for two indications
20 Feb 2025 //
PRESS RELEASE
FDA Grants Priority Review To Merck’s WELIREG® For PPGL Treatment
28 Jan 2025 //
PHARMAWEB
FDA Grants Priority Review to Merck’s WELIREG for PPGL Treatment
27 Jan 2025 //
BUSINESSWIRE
Merck`s WELIREG® Gets EU Nod For VHL Tumors & Advanced RCC
13 Dec 2024 //
BUSINESSWIRE
Exelixis And Merck Sign Clinical Development Collaboration
14 Oct 2024 //
BUSINESSWIRE
HiberCell: First Patient Dosed In Merck Combo Trial For ccRCC
01 May 2024 //
GLOBENEWSWIRE
US FDA approves Merck`s drug for kidney cancer
14 Dec 2023 //
REUTERS
At ESMO, Merck touts Welireg`s potential in kidney cancer
21 Oct 2023 //
FIERCE PHARMA
Merck’s WELIREG Improved Objective Response Rates Versus Everolimus in RCC
21 Oct 2023 //
BUSINESSWIRE
FDA Accepts for Priority Review Merck’s Supplemental NDA for WELIREG
19 Sep 2023 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.